EN DE

IHH HEALTHCARE BERHAD (Q0F) Fair Value & Analysis

Healthcare · SG · Market cap 25.1B SGD (≈ $19.8B)

What is IHH HEALTHCARE BERHAD really worth?

IH IHH HEALTHCARE BERHAD Q0F · SG
Price2.66 SGD
Fair Value1.44 SGD
Upside−45.9%
Quality52/100

A solid business, but trading 85% above our fair value of 1.44 SGD.

Watch IHH HEALTHCARE BERHAD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 5y +13.9 %/yr)
✓Low debt · generates free cash flow

Risks

!Thin margins · 8.1% net margin
!Mixed vs. peers (8/15)
!Narrow moat 43/100
!Weak on future: 21 out of 100

For context

·3.95% dividend yield
Evidence: High Range 0.9000 SGD – 1.80 SGD

Fair value as of: Aug 13, 2026

From 24 valuation models · updated 22 days ago

Share price −0.7% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (1.80 SGD). The favourable scenario is already priced in.
  • Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (0.9000 SGD to 1.80 SGD) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

3.05 SGD 1.58 SGD Fair Value 1.44 SGD Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 1.58 SGD – 3.05 SGD · fair‑value band 0.9000 SGD – 1.80 SGD · the 2.66 SGD price screens above the 1.44 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

IHH HEALTHCARE BERHAD (Q0F) currently trades at 2.66 SGD, while our model-based Fair Value estimate is 1.44 SGD, implying the stock looks roughly 84.7% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of 5.49 SGD per share, and 22 of the 24 models we run sit above the 2.66 SGD price. Bear case: the Asset-Based group reads lowest at 2.30 SGD, and 2 of the 24 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, IHH HEALTHCARE BERHAD generated revenue of 26.0B SGD at a net margin of 8.1%. Revenue grew 4.1% year over year. It earns a return on equity of 7.9%. Net debt stands at 11.8B SGD. Fundamentals as of Aug 13, 2026

Our scenario range runs from 0.9000 SGD (bear case) to 1.80 SGD (bull case); at 2.66 SGD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 43% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −46%, Q0F screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 2.77 SGD 2.92 SGD 3.11 SGD 76
FCF DCF 2.14 SGD 4.60 SGD 8.97 SGD 75
EPV 2.90 SGD 3.50 SGD 4.03 SGD 74
All 24 models by family
DCF Models
FCF DCF 2.14 SGD 4.60 SGD 8.97 SGD 75
Owner Earnings — 0.2400 SGD 1.01 SGD 73
5Y Revenue Exit 2.94 SGD 6.14 SGD 10.59 SGD 70
5Y EBITDA Exit 4.60 SGD 9.62 SGD 16.08 SGD 72
5Y P/E Exit 2.70 SGD 5.62 SGD 9.03 SGD 68
10Y Revenue Exit 2.52 SGD 5.49 SGD 10.25 SGD 63
10Y EBITDA Exit 3.76 SGD 8.06 SGD 14.93 SGD 65
10Y P/E Exit 2.49 SGD 5.10 SGD 8.92 SGD 61
Earnings-Based
Graham-Dodd 1.62 SGD 7.98 SGD 11.00 SGD 64
Lynch FV 2.15 SGD 3.07 SGD 3.99 SGD 61
PEG = 1.0 2.15 SGD 3.07 SGD 3.99 SGD 57
EPV 2.90 SGD 3.50 SGD 4.03 SGD 74
Multiples
P/E Multiple 3.92 SGD 5.23 SGD 6.54 SGD 63
P/S Multiple 3.03 SGD 4.04 SGD 5.05 SGD 58
P/B Multiple 3.03 SGD 4.04 SGD 5.05 SGD 55
EV/EBIT 4.95 SGD 6.83 SGD 8.71 SGD 66
EV/EBITDA 6.22 SGD 8.53 SGD 10.83 SGD 67
EV/Revenue 3.33 SGD 5.06 SGD 6.78 SGD 53
Asset-Based
NCAV (Graham) 1.71 SGD 2.30 SGD 3.43 SGD 54
Growth DCF
Growth DCF 2.11 SGD 4.32 SGD 8.14 SGD 74
Rev-Margin DCF 2.94 SGD 6.02 SGD 10.06 SGD 70
Economic Profit
Residual Income 2.77 SGD 2.92 SGD 3.11 SGD 76
ROIC Compounder 2.90 SGD 3.60 SGD 4.89 SGD 72
Growth Earnings
Growth-Adj P/E 3.39 SGD 4.84 SGD 6.30 SGD 67

Widest divergence: DCF Models (5.49 SGD) versus Asset-Based (2.30 SGD). Highest evidence: Residual Income (76).

Notify me when Q0F reaches fair value

Put Q0F on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 32.3
P/S ratio 2.64 P/E × margin
EPS (TTM) 0.0800 SGD price ÷ EPS = P/E 32.3
Dividend yield 3.9% payout 131%
Net margin 8.2% FY2025
Return on equity 7.9% TTM
More key figures
Profitability
Return on assets (EBIT) 6.8% avg 5y
Operating margin 14.5% TTM
Growth
Revenue (TTM) 26.0B SGD TTM
Revenue growth (YoY) +4.1% 3y avg +12.7%
EPS growth (YoY) +2.5%
Balance sheet & cash flow
Free cash flow 1.9B SGD FY2025
Net debt 11.8B SGD FY2025 · ≈ 6.2 yrs of FCF

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 52/100

Of which business quality 52 · Market factors (momentum, volatility) 65

Profitability 39
Margins and returns on capital today
Quality Growth 44
Are margins and returns improving?
Cashflow 54
Earnings quality: real cash, not paper profit
Fin. Strength 44
Balance sheet, leverage, solvency risk
Investment 59
Disciplined investing over empire-building
Low Volatility 87
Calm price path (market factor)
Momentum 48
Price trend over the last 3–12 months (market factor)
52W Momentum 67
Distance to the 52-week high (market factor)
Net Issuance 80
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services.

Full company description

IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services. The company also offers secondary care facilities, including medical emergencies and acute treatment, as well as specialist consultation, diagnostics, and lab services; tertiary care services comprising specialist consultative care, advanced treatment, complex surgery, and inpatient care services; and quaternary care services, such as organ transplants, neurosurgery, cardiac surgery, and reconstructive plastic surgery. In addition, it provides ancillary services, including diagnostics, laboratory testing, radiology, physiotherapy, and integrated rehabilitation and advanced molecular diagnostics services. Further, the company offers medical education; train and develop nurses, doctors, clinicians, and allied healthcare professionals; administrative, management, consultancy services; emergency, home, and ambulatory care services; healthcare information systems, web-based applications, and other technology solutions; and real estate investment trust services. Additionally, it provides services for medical diagnostic laboratory tests; develops, constructs, and leases medical facility buildings and healthcare facilities; provides catering, laundry, and cleaning services for hospitals; and haemodialysis services, as well as imports and wholesales drug and medical materials. The company engages in the letting of properties; and computer software designing, development, customization, integration, implementation, maintenance, and related services. IHH Healthcare Berhad was incorporated in 2010 and is based in Kuala Lumpur, Malaysia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

IHH HEALTHCARE BERHAD reported revenue of 25.7B MYR in FY2025 versus 17.1B MYR in FY2021, a compound +10.7%/yr. Reported net income was 2.1B MYR in FY2025, compounding +3.1%/yr from FY2021.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
25.7B SGD
Latest YoY
+5.6%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.7%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.9%
Avg. revenue growth/yr (12Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.8%
Value creation/yr (5Y, in MYR) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+34.4% (30.5 + 3.9)
Revenue +10.7%/yr
FY21 17.1B MYR
FY22 18.0B MYR
FY23 20.9B MYR
FY24 24.4B MYR
FY25 25.7B MYR
Net income +3.1%/yr
FY21 1.9B MYR
FY22 1.5B MYR
FY23 3.0B MYR
FY24 2.7B MYR
FY25 2.1B MYR

Q0F screens 85% overvalued. Compare with HCA Healthcare, Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IHH HEALTHCARE BERHAD · Fair Value
1.44 SGD −85%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "IHH HEALTHCARE BERHAD Fair Value". https://www.fairvalue-calculator.com/stock/Q0F

Peer Group

Medical Care Facilities · 257 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 52 · Below median
Fair Value upside −46% · Bottom 25%
Return on equity (TTM) 8% · Above median
Return on assets 4% · Above median
Net margin (TTM) 8% · Above median
Operating margin (TTM) 15% · Above median
Revenue growth 4% · Below median
Dividend yield (TTM) 3.9% · Top 25%
Debt / equity 0.26× · Higher than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 32.3× · Pricier than median
P/B 0.65× · Cheaper than 75% of peers
P/S (TTM) 0.76× · Cheaper than median
P/FCF 10.4× · Pricier than 75% of peers
EV/EBITDA 4.9× · Cheaper than 75% of peers
PEG 4.18× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 23
FUTURE21 · sector 26
PAST32 · sector 30
HEALTH87 · sector 90
DIVIDEND79 · sector 43

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $417.82 $547.67 +31%
Fresenius SE FRE €45.25 €32.15 −29%
Dr. Sulaiman Al Habib Medical Services Group 4013 241.00 SAR 112.37 SAR −53%
Tenet Healthcare Corporation THC $266.80 $330.25 +24%
DaVita Inc DVA $180.68 $186.49 +3%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,818 ₹2,955 −66%
Fresenius Medical Care AG FME €39.92 €71.28 +79%
Aier Eye Hospital Group 300015 ¥8.25 ¥7.67 −7%
Max Healthcare Institute Limited MAXHEALTH ₹1,005 ₹284.87 −72%
Encompass Health Corporation EHC $120.31 $109.77 −9%

Compare IHH HEALTHCARE BERHAD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is IHH HEALTHCARE BERHAD (Q0F) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 1.44 SGD versus a price of 2.66 SGD, about −46% upside (overvalued).
What is the fair value of Q0F?
Our model-based fair value for IHH HEALTHCARE BERHAD is 1.44 SGD (as of Aug 13, 2026), built from audited fundamentals. The current price: 2.66 SGD.
What is the quality score of Q0F?
IHH HEALTHCARE BERHAD has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of IHH HEALTHCARE BERHAD (Q0F)?
IHH HEALTHCARE BERHAD reported trailing-twelve-month revenue of about 26.0B SGD (latest available figure, as of Aug 13, 2026).
What is the net profit margin of Q0F?
The net profit margin of IHH HEALTHCARE BERHAD is about 8.1%, meaning it keeps roughly 8.1% of revenue as net income. Based on the latest reported figures.
Does IHH HEALTHCARE BERHAD pay a dividend?
IHH HEALTHCARE BERHAD currently shows a dividend yield of about 3.95% relative to its recent price (as of Aug 13, 2026).
Free · no account needed

Watch IHH HEALTHCARE BERHAD in the live analysis

One click puts IHH HEALTHCARE BERHAD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.